Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone Disease

European Heart Journal

Volumn 36, Issue 25, 2015, Pages 1601-1608

  Lauridsen, Bo Kobberø ^a   Stender, Stefan ^a   Frikke Schmidt, Ruth ^a,b   Nordestgaard, Børge G ^b,c,d   Tybjærg Hansen, Anne ^a,b,d  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Cardiovascular diseases; Cholesterol; Genetics

Indexed keywords

CHOLESTEROL; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIEMANN PICK C1 LIKEPROTEIN 1; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG8 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN; NPC1L1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; VASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG COMBINATION; GALLSTONE; GENETICS; HEART INFARCTION; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MENDELIAN RANDOMIZATION ANALYSIS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

AGED; ANTICHOLESTEREMIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; GALLSTONES; GENETIC VARIATION; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ISCHEMIA; LIPID METABOLISM; MALE; MEMBRANE PROTEINS; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; STROKE;

EID: 84939527545     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv108     Document Type: Article

References (35)

1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
2. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KASr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J Am Coll Cardiol 2012;60:2631-2639.
3. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
4. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-2205.
5. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
6. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24: 729-741.
7. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356.
8. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-2122.
9. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-8137.
10. Khanderia U, Regal RE, Rubenfire M, Boyden T. The ezetimibe controversy: implications for clinical practice. Ther Adv Cardiovasc Dis 2011;5:199-208.
11. IMPROVE, -IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-832.
12. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007;117:1968-1978.
13. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006; 368:230-239.
14. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010;55:2833-2842.
15. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in apoc3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32-41.
16. Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 2012;60:2041-2048.
17. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-1163.
18. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigators. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J Lipid Res 2010;51:1201-1207.
19. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-1283.
20. Martín B, Solanas-Barca M, García-Otín AL, Pampín S, Cofán M, Ros E, Rodríguez-Rey JC, Pocoví M, Civeira F. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutr Metab Cardiovasc Dis 2010;20:236-242.
21. Chen CW, Hwang JJ, Tsai CT, Su YN, Hsueh CH, Shen MJ, Lai LP. The g.-762T.C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels. J Hum Genet 2009; 54:242-247.
22. Alrefai WA, Annaba F, Sarwar Z, Dwivedi A, Saksena S, Singla A, Dudeja PK, Gill RK. Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: Role of sterol regulatory element binding protein 2. Am J Physiol Gastrointest Liver Physiol 2007;292:G369-G376.
23. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62 000 individuals from the general population. Hepatology 2011; 53:640-648.
24. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-436.
25. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease. J Am Coll Cardiol 2014;63:2121-2128.
26. Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 2003;278:48275-48282.
27. Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol 2012;36:122-129.
28. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. JAMA Intern Med 2013;173:1222-1228.
29. Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371: 2072-2082.
30. Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302:2001-2007.
31. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009;136:1593-1600.
32. Altemus JB, Patel SB, Sehayek E. Liver-specific induction of Abcg5 and Abcg8 stimulates reverse cholesterol transport in response to ezetimibe treatment. Metabolism 2014;63:1334-1341.
33. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ.Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008; 134:2101-2110.
34. Zúñiga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, Arrese M, Lammert F, Miquel JF. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008;28:935-947.
35. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204.